


For the adjunctive treatment of oral inflammatory and ulcerative lesions<sup>1</sup>

# Sticktoitiveness



Aphthous Ulcer

**Oralone<sup>®</sup> adheres to oral lesions providing targeted anti-inflammatory therapy<sup>1</sup>**

*Oral Triamcinolone Acetonide Dental Paste 0.1% is a mid-potency<sup>2</sup> steroid in a muco-adhesive base*

Oralone<sup>®</sup> (Triamcinolone Acetonide Dental Paste USP, 0.1%) is indicated for adjunctive treatment and for the temporary relief of symptoms associated with oral inflammatory lesions and ulcerative lesions resulting from trauma. The following local adverse reactions may occur with corticosteroid-containing dental pastes: burning, itching, irritation, dryness, blistering or peeling not present prior to therapy, perioral dermatitis, allergic contact dermatitis, maceration of the oral mucosa, secondary infection, and atrophy of the oral mucosa.

Oralone<sup>®</sup> is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation; it is also contraindicated in the presence of fungal, viral, or bacterial infections of the mouth or throat. Oralone<sup>®</sup> may cause local adverse reactions. If irritation develops, Oralone<sup>®</sup> should be discontinued and appropriate therapy instituted.

See package insert for full prescribing information.



**Oralone<sup>®</sup>**  
**Triamcinolone Acetonide**  
**Dental Paste USP, 0.1%**

# Sticktoitiveness

– what it means for you and your patients

## Lesion adhesion


- Oralone's muco-adhesive base facilitates targeted delivery of Triamcinolone Acetonide. Early initiation of treatment may result in a more rapid response <sup>3</sup>

## Sticking around

- Triamcinolone Acetonide Dental Paste USP 0.1% was first approved by the FDA in 1960 (Kenalog in Orabase®)\*—meaning it has a track record of nearly 50 years <sup>4</sup>

## A value proposition sure to stick

- Taro is the sole manufacturer of Oralone® and its generic, so patients can receive brand-quality treatment at a generic price



\*Oralone® is equivalent to Kenalog in Orabase®, which is no longer available.

### References:

1. Oralone package insert, TaroPharma, Hawthorne, NY. 2. Hardman JG, Limbird LE, Gilman AF, eds. Goodman and Gilman's The Pharmacologic Basis of Therapeutics Tenth Edition. McGraw-Hill, New York, 2001, pp. 1799-1800.3. Burgess JA, Johnson BD, Sommers E. Pharmacological management of recurrent oral mucosal ulceration. Drugs 1990;39(1):54-65. 4. Data on file, TaroPharma, Hawthorne, NY.

**Sticktoitiveness—**  
*Oralone*® adheres to oral lesions providing targeted anti-inflammatory therapy



*Oralone*®  
Triamcinolone Acetonide  
Dental Paste USP, 0.1%



a division of Taro Pharmaceuticals U.S.A., Inc  
3 Skyline Drive, Hawthorne, NY 10532  
www.taropharma.com

SM910-0006 © 2009 Taro Pharmaceuticals U.S.A., Inc